Group 1 - In the first quarter, the profits of industrial enterprises above designated size turned from a year-on-year decline of 3.3% in the previous year to a growth of 0.8% [2][5] - In March, the profits of these enterprises increased by 2.6%, reversing a 0.3% decline in January and February [6][8] - The revenue of industrial enterprises in March grew by 4.2%, accelerating by 1.4 percentage points compared to January and February [6][8] Group 2 - High-tech manufacturing profits surged by 14.3% in March, contributing 2.8 percentage points to the overall profit growth of industrial enterprises [3][8] - The specialized and general equipment sectors saw profit increases of 14.2% and 9.5%, respectively, outperforming the average profit growth of all industrial enterprises [3][8] - In the first quarter, 24 out of 41 industrial categories reported profit growth, indicating nearly 60% of industries experienced improvements [8] Group 3 - The private and joint-stock enterprises showed significant profit growth in March, with private enterprises increasing by 16.0% and joint-stock enterprises by 3.5% [7] - The equipment manufacturing sector accounted for 32.0% of the total profits of industrial enterprises, with a year-on-year profit growth of 6.4% [8] - The aerospace industry experienced a profit increase of 23.9%, while sectors like smart consumer devices and medical equipment also reported substantial profit growth [8]

Core Viewpoint - The company focuses on providing integrated digital solutions in the life sciences and medical innovation sectors, leveraging advanced technologies to enhance user experience and drive industry transformation [5][6][25]. Company Overview - The company operates in two main segments: life sciences and medical innovation, offering solutions such as smart laboratories and digital hospitals [5]. - The company has established a strong global presence, with products and solutions applied in over 150 countries and regions [6][26]. Business Model - The company maintains a comprehensive control over the entire process from research and development to sales and after-sales service [7]. - The procurement process involves rigorous supplier qualification and just-in-time inventory management [8]. Industry Situation - The life sciences and medical innovation sectors are experiencing growth driven by increased demand for integrated solutions and advancements in technology [12][21]. - The global life sciences tools market is projected to reach $330.69 billion by 2030, with significant growth in the Asia-Pacific region [12]. Technological Advancements - The company has developed six major technology platforms and holds 1,595 patents, positioning itself as a leader in biomedicine and low-temperature technology [25]. - The integration of IoT, cloud computing, and AI into the company's offerings is expected to enhance operational efficiency and user experience [27][28]. Financial Highlights - The company plans to distribute a cash dividend of 4.7 yuan per 10 shares, totaling approximately 147.8 million yuan [3]. Future Development Trends - The industry is shifting towards automation and intelligent solutions, with a focus on enhancing operational efficiency and reducing costs [28][29]. - The company aims to capitalize on the growing demand for digital solutions in healthcare, driven by national policies and technological advancements [17][19][31].

本次发行股票拟在科创板上市，科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者应 充分了解科创板的投资风险及本公司所披露的风险因素，审慎作出投资决定。 杭州安杰思医学科技股份有限公司 （浙江省杭州市余杭区康信路 597 号 5 幢、6 幢（除 103 室、202 室）） 首次公开发行股票并在科创板上市 招股说明书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 杭州安杰思医学科技股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 杭州安杰思医学科技股份有限公司 招股说明书 本次发 ...

本次发行股票拟在科创板上市，科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者应 充分了解科创板的投资风险及本公司所披露的风险因素，审慎作出投资决定。 杭州安杰思医学科技股份有限公司 （浙江省杭州市余杭区康信路 597 号 5 幢、6 幢（除 103 室、202 室）） 首次公开发行股票并在科创板上市 招股意向书 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 保荐人（主承销商） 杭州安杰思医学科技股份有限公司 招股意向书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 杭州安杰思医学科技股份有限公司 招股意向书 本次发 ...

本次发行股票拟在科创板上市，科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者 应充分了解科创板的投资风险及本公司所披露的风险因素，审慎作出投资决 定。 杭州安杰思医学科技股份有限公司 （浙江省杭州市余杭区康信路 597 号 5 幢、6 幢（除 103 室、202 室）） 首次公开发行股票并在科创板上市 招股说明书 （注册稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。 本招股说明书（注册稿）不具有据以发行股票的法律效力，仅供预先披露之 用。投资者应当以正式公告的招股说明书全文作为作出投资决定的依据。 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 杭州安杰思医学科技股份有限公司 招股说明书（注册稿） 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收 ...